Procalcitonin Blood Test Explained: What It Measures and Why It's Ordered

Procalcitonin (often abbreviated PCT) is one of the more widely discussed infection-related biomarkers in hospital medicine. This page summarises what the published literature says the analyte is, how laboratories measure it, the clinical questions it has been studied against, and the caveats reviews raise about interpretation. This page is for educational purposes only and is not medical advice; consult a licensed physician or the clinician who requested the test about any individual result.

What procalcitonin is and where it comes from

Procalcitonin is a 116-amino-acid peptide precursor of calcitonin, the calcium-regulating hormone produced by the parafollicular C cells of the thyroid gland. Under normal physiological conditions, the precursor is processed intracellularly within those C cells and very little intact procalcitonin escapes into the circulation, so concentrations in healthy people are extremely low.

The reason the molecule became a laboratory test is that during systemic bacterial infection and severe inflammation, transcription of the calcitonin-related gene is induced in many extrathyroidal tissues, and the unprocessed precursor is released into blood. A European review of procalcitonin and sepsis in the emergency department described this inflammatory induction as the basis for the marker's use in suspected systemic infection (https://pubmed.ncbi.nlm.nih.gov/33506938/). A practical teaching review aimed at paediatric clinicians similarly framed procalcitonin as a host-response marker rather than a direct test for any organism (https://pubmed.ncbi.nlm.nih.gov/29343506/).

Two consequences follow from that biology and recur throughout the literature. First, procalcitonin reflects the host's inflammatory response, not the presence of bacteria themselves. Second, because the calcitonin precursor also originates from thyroid C cells, tumours of those cells can raise circulating levels for reasons that have nothing to do with infection.

What the procalcitonin blood test measures

The test is performed on a standard venous blood sample, processed as serum or plasma, and analysed by immunoassay. Modern platforms generally use sandwich immunoassay formats with chemiluminescent, electrochemiluminescent, fluorescent or enzyme-linked detection; semi-quantitative rapid immunochromatographic strips also exist and were historically used where automated platforms were unavailable. Assays differ in their lower limit of detection, which matters because clinical decision points in the literature sit at low absolute concentrations.

Results are reported as a concentration in nanograms per millilitre (ng/mL, equivalent to µg/L). Laboratories publish their own reference intervals and functional sensitivity, and reviews repeatedly emphasise that a value is read in the context of the clinical picture, the timing of the sample relative to symptom onset, and the trend across serial measurements rather than as a stand-alone verdict (https://pubmed.ncbi.nlm.nih.gov/33506938/).

Why clinicians request the test, according to the literature

Suspected sepsis and undifferentiated acute illness

The best-described use is in patients presenting with suspected severe bacterial infection. An emergency-department-focused review summarised procalcitonin as an adjunct for recognising sepsis and for risk stratification alongside clinical scores, while cautioning that it does not replace clinical judgement or cultures (https://pubmed.ncbi.nlm.nih.gov/33506938/). In paediatrics, a review of procalcitonin as a sepsis biomarker in children examined its diagnostic performance across age groups and settings and discussed how results are combined with other data rather than used in isolation (https://pubmed.ncbi.nlm.nih.gov/32350044/).

Lower respiratory tract infection

A 2020 systematic review and meta-analysis assessed whether procalcitonin could separate viral from bacterial pneumonia and reported that, although levels tended to be higher in bacterial cases, no single cut-off discriminated the two aetiologies reliably enough to be used alone for that decision (https://pubmed.ncbi.nlm.nih.gov/31241140/). In critical care, an older review of diagnostic and prognostic markers for ventilator-associated pneumonia placed procalcitonin among the candidate markers studied for distinguishing infection from colonisation and for tracking response in mechanically ventilated patients (https://pubmed.ncbi.nlm.nih.gov/16943724/).

Antimicrobial stewardship

A pharmacy-focused guidance review examined procalcitonin-informed antimicrobial decisions in special patient populations, including how trends have been used to support stopping or continuing antibiotics, and detailed the populations in which that approach has been studied least (https://pubmed.ncbi.nlm.nih.gov/32340027/). The paediatric teaching review likewise discussed procalcitonin in the context of limiting unnecessary antibiotic exposure while flagging the limits of the evidence (https://pubmed.ncbi.nlm.nih.gov/29343506/).

Central nervous system infection

A literature review of procalcitonin in meningitis evaluated serum procalcitonin as a discriminator between bacterial and viral meningitis and concluded it performed better than several conventional markers for that distinction while still being interpreted alongside cerebrospinal fluid findings (https://pubmed.ncbi.nlm.nih.gov/29891780/). An earlier study of serum procalcitonin in cerebral ventriculitis examined the marker in patients with ventricular drains and device-associated central nervous system infection (https://pubmed.ncbi.nlm.nih.gov/12163792/).

Infected necrosis in pancreatitis

A clinical surgery study of biological markers in acute necrotic pancreatitis assessed procalcitonin among markers used to detect purulent–septic complications, a setting where distinguishing sterile inflammation from infected necrosis changes management (https://pubmed.ncbi.nlm.nih.gov/30479110/).

What published studies associate with high values

Reviews consistently describe marked elevations in systemic bacterial infection and sepsis, with the degree of elevation tending to track severity (https://pubmed.ncbi.nlm.nih.gov/33506938/). Beyond that core association, the literature documents several other sources of elevated values:

• Infected pancreatic necrosis. The pancreatitis marker study investigated procalcitonin as a signal of purulent–septic complications rather than of pancreatitis itself (https://pubmed.ncbi.nlm.nih.gov/30479110/).
• Medullary thyroid carcinoma. A review of the diagnostic challenges of medullary thyroid carcinoma discussed procalcitonin as a tumour-related analyte in this C-cell malignancy, which secretes calcitonin and its precursors (https://pubmed.ncbi.nlm.nih.gov/33878761/).
• Liver disease. A literature review on procalcitonin and liver disease described altered baseline concentrations and altered diagnostic performance in patients with cirrhosis and other hepatic conditions (https://pubmed.ncbi.nlm.nih.gov/30944820/).
• Inflammatory bowel disease. A review of procalcitonin in inflammatory bowel disease examined both the drawbacks of elevation driven by non-infectious bowel inflammation and the opportunities for separating flares from superimposed infection (https://pubmed.ncbi.nlm.nih.gov/29307988/).
• Special populations. The antimicrobial-guidance review catalogued populations — including patients with renal impairment, burns, trauma, surgery and immunosuppression — in which baseline or stimulus-driven procalcitonin behaves differently from the general ward population (https://pubmed.ncbi.nlm.nih.gov/32340027/).

What studies associate with low or undetectable values

Low concentrations have been studied mainly for their negative predictive value: in several settings, a low result made systemic bacterial infection less likely and was examined as support for withholding or discontinuing antibiotics (https://pubmed.ncbi.nlm.nih.gov/32340027/). That reasoning has limits. Localised infections without a systemic inflammatory response, very early sampling before the marker has risen, and some indolent or encapsulated infections can occur with unremarkable values, and the paediatric review stressed that a single low measurement does not exclude serious bacterial infection in a child who looks unwell (https://pubmed.ncbi.nlm.nih.gov/29343506/). The pneumonia meta-analysis made the parallel point for respiratory infection, reporting that low values did not reliably rule out a bacterial cause (https://pubmed.ncbi.nlm.nih.gov/31241140/).

Clinical questions studied, at a glance

Assay and interpretation caveats described in reviews

Kinetics and timing

Procalcitonin does not rise instantaneously. Reviews describe a lag between the inflammatory stimulus and a measurable increase, which is why serial sampling and trend interpretation feature so prominently in the sepsis literature (https://pubmed.ncbi.nlm.nih.gov/33506938/). A sample drawn very early in an illness can understate what a later sample would show, and researchers writing for paediatric practice highlighted timing as a common source of misinterpretation (https://pubmed.ncbi.nlm.nih.gov/29343506/).

Non-infectious elevation

Because the marker reflects systemic inflammation and C-cell biology, it can be elevated without bacterial infection. Medullary thyroid carcinoma is the clearest tumour-related example discussed in the diagnostic-challenges review (https://pubmed.ncbi.nlm.nih.gov/33878761/), and non-infectious intestinal inflammation was addressed in the inflammatory bowel disease review (https://pubmed.ncbi.nlm.nih.gov/29307988/).

Comorbidity shifts the baseline

The liver disease review described how hepatic impairment complicates interpretation, so a value that would be unremarkable in one patient may not carry the same meaning in another (https://pubmed.ncbi.nlm.nih.gov/30944820/). The special-populations guidance made the same argument across renal, surgical, burn and immunocompromised groups (https://pubmed.ncbi.nlm.nih.gov/32340027/).

Cut-offs are not universal

Decision thresholds reported in studies were derived in specific populations and with specific assays, and performance shifted when the setting changed; the pneumonia meta-analysis illustrated how a threshold that looked useful in one cohort did not generalise (https://pubmed.ncbi.nlm.nih.gov/31241140/). Cross-platform differences between immunoassays mean that values from different laboratories are not always directly comparable.

What the test does not do

Procalcitonin does not identify an organism, does not replace blood or cerebrospinal fluid cultures, and does not locate a source of infection. Across the reviews summarised here, it was consistently positioned as one input among history, examination, imaging, microbiology and other laboratory results (https://pubmed.ncbi.nlm.nih.gov/33506938/, https://pubmed.ncbi.nlm.nih.gov/32350044/). Interpretation of any individual result — including whether a value is high, what might explain it, and what should happen next — belongs to the clinician who requested the test and has access to the full clinical context.

References

• Procalcitonin and sepsis in the Emergency Department: an update (European Review for Medical and Pharmacological Sciences, 2021)
• Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis (Clinical Infectious Diseases, 2020)
• Role of Biological Markers in Diagnosis of Purulent—Septic Complications of an Acute Necrotic Pancreatitis (Klinichna Khirurhiia, 2016)
• How to use… Procalcitonin (Archives of Disease in Childhood: Education and Practice Edition, 2018)
• Diagnostic Challenges of Medullary Thyroid Carcinoma (Oncology, 2021)
• Procalcitonin and Liver Disease: A Literature Review (Journal of Clinical and Translational Hepatology, 2019)
• Utility of Procalcitonin as a Biomarker for Sepsis in Children (Journal of Clinical Microbiology, 2020)
• Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities (World Journal of Gastroenterology, 2017)
• The Role of Procalcitonin in the Diagnosis of Meningitis: A Literature Review (Journal of Clinical Medicine, 2018)
• Serum procalcitonin in cerebral ventriculitis (Critical Care Medicine, 2002)
• New diagnostic and prognostic markers of ventilator-associated pneumonia (Current Opinion in Critical Care, 2006)
• Procalcitonin in special patient populations: Guidance for antimicrobial therapy (American Journal of Health-System Pharmacy, 2020)